1. Medtech Insight
  2. >>Geography
  3. >>Europe

What Does The EU Regulation On HTA Mean For Medtech And When Will It Apply?

 
• By Eliza Slawther

Several updates have come in recent weeks on the European Commission’s planned new Regulation on HTA, including a list of stakeholder members and updated rolling timeline. Medtech Insight explains how and when this legislation will affect the medtech sector.

Medical Software
• Source: Shutterstock

Health technology assessment (HTA) processes for drugs and medical devices are currently the sole responsibility of individual member states, but the new EU HTA Regulation will set a legal framework for joint, EU-level assessment processes and common methodologies.

What Is HTA?

Health technology assessment is a means of evaluating a medical product for its clinical and cost-effectiveness, taking into consideration clinical evidence, a comparison to existing therapies/devices and many other socio-economic and ethical factors.

It is crucial to note that the HTA Regulation will focus solely on comparing the clinical evidence available for new products to that of similar existing therapies at an EU-level. How these reports are interpreted for reimbursement decisions will be up to individual member states.

Assessments carried out under the HTA Regulation also will not dictate how member states allocate their national health budgets or decide which products to reimburse.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

How Notified Bodies Would Like Future EU Medtech Governance To Pan Out

 
• By Amanda Maxwell

Notified bodies are calling for their key role, as the technical, regulatory and clinical ‘extended arm’ of regulatory authorities, to remain central to the EU medtech conformity assessment process.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

More from Geography

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

Award-Winning Lioness Implant Addresses ‘Silent Emergency’ Of Preterm Birth

 
• By Ashley Yeo

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.